Skip to content
ApprovedFDA approved

Finasteride

Selective inhibitor of type II 5-alpha-reductase. FDA-approved for androgenetic alopecia (Propecia 1 mg) and BPH (Proscar 5 mg). Reduces DHT formation by ~70%.

Finasteride vial

Related comparisons

Finasteride vs Dutasteride

WHAT IS FINASTERIDE?

Detailed overview

Finasteride is a synthetic 4-azasteroid developed by Merck (Proscar for BPH, FDA 1992; Propecia for alopecia, FDA 1997). It is a selective inhibitor of the type II 5-alpha-reductase enzyme, blocking the conversion of testosterone to dihydrotestosterone (DHT) in the prostate and hair follicles. DHT is the primary driver of hair follicle miniaturization (androgenetic alopecia) and prostate growth (BPH). According to the Kaufman 1998 RCT (PMID 9591820), at 24 months hair growth was documented in 48% of alopecia patients and hair stabilization in 90%. According to the Roehrborn 2002 MTOPS trial (NEJM PMID 12944571), it reduces BPH progression by 39% as monotherapy. The difference between ATC codes D11AX10 (alopecia 1 mg) and G04CB01 (BPH 5 mg) is only the dose and the indication.

ATC code

D11AX10 (1mg) / G04CB01 (5mg)

Prescription status

Prescription only (Rx)

Mechanism of action

Selective inhibition of type II 5-alpha-reductase, ~70% DHT reduction

Half-life

5-6 hours plasma, 96+ hours enzyme affinity

Onset of action

3-6 months (hair stabilization), 6-12 months (regrowth)

Data console

Lab data

/lab/molecular-data.jsonLIVE
> Classification-
> StructureN/A
> Molecular weightN/A
> Target area-
> Storage2–8°C
> Stability~30 days reconstituted

Safety

Side effects, stop signs, contraindications

Side effects · 7

  • Sexual side effects: decreased libido (~1.8%), erectile dysfunction (~1.3%), ejaculation disorder and reduced ejaculate volume (~1%); usually reversible after discontinuation.
  • Mood disorders: depression, anxiety and (rarely) suicidal ideation reported; the FDA label warns of this, discontinue and seek medical advice if psychiatric symptoms occur.
  • Breast changes: gynaecomastia (breast enlargement), breast tenderness and pain; rarely a breast lump, pain or nipple discharge that must be evaluated (male breast cancer rarely reported).
  • PSA decreases by ~50%: prostate-specific antigen becomes falsely low, so during prostate cancer screening the measured PSA must be doubled to avoid a false negative.
  • Hypersensitivity and skin reactions: rash, pruritus, urticaria, swelling of the lips and face (angioedema); rarely an allergic reaction requiring immediate discontinuation.
  • Slightly increased incidence of high-grade prostate cancer (Gleason 8-10) in the PCPT trial, while overall prostate cancer risk fell; with no difference in overall survival.
  • Disputed persistent (post-finasteride) symptoms: sexual, mood and cognitive complaints persisting after stopping in a small fraction; clinically debated but listed in the patient information.

Contraindications · 3

  • Pregnancy (FDA category X)
  • Women of childbearing age
  • Hypersensitivity

Related Hair & Skin

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about Finasteride?

Educational hair and skin info from official sources (PubMed, FDA, EMA). Does NOT replace medical consultation. Talk to a dermatologist!

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: June 19, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.